Type 2 diabetes and treatment intensification in primary care in Finland

Show full item record




Niskanen , L , Hahl , J , Haukka , J , Leppä , E , Miettinen , T , Mushnikov , V , Sipilä , R , Tamminen , N , Vattulainen , P & Korhonen , P 2018 , ' Type 2 diabetes and treatment intensification in primary care in Finland ' , Acta Diabetologica , vol. 55 , no. 11 , pp. 1171-1179 . https://doi.org/10.1007/s00592-018-1199-7

Title: Type 2 diabetes and treatment intensification in primary care in Finland
Author: Niskanen, Leo; Hahl, Jarmo; Haukka, Jari; Leppä, Elli; Miettinen, Tatu; Mushnikov, Vasili; Sipilä, Raija; Tamminen, Nadia; Vattulainen, Pia; Korhonen, Pasi
Contributor organization: Endokrinologian yksikkö
Department of Medicine
Jari Haukka / Principal Investigator
Department of Public Health
University of Helsinki
HUS Abdominal Center
Date: 2018-11
Language: eng
Number of pages: 9
Belongs to series: Acta Diabetologica
ISSN: 0940-5429
DOI: https://doi.org/10.1007/s00592-018-1199-7
URI: http://hdl.handle.net/10138/253472
Abstract: AimTo identify how the electronic health record (EHR) systems and national registers can be used for research purposes. We focused on how the primary care physicians adhere to clinical guidelines.MethodsStudy population included incident type 2 diabetes patients from four selected regions. Data were collected in two phases. At the first phase study cohort was identified using the prescription registers of the Social Insurance Institution (SII) and EHR systems used within the study regions. At second phase, data were collected from SII's registers, local EHR systems, the hospital discharge and the primary care registers of National Institute for Health and Welfare.ResultsMetformin was the most common choice as first drug. Among all study patients, 8375 (76.0%) started metformin monotherapy or combinations. The treatment was intensified at variable levels of HbA1c depending on the area. DPP4-inhibitors were by far the most common agent for treatment intensification. Sulphonylureas were used less often than basal insulin as the second-line agent. The use of DPP4-inhibitors increased between years 2009-2010, when first DPP4-inhibitor received reimbursement and this class became dominant drug for treatment intensification increasingly thereafter.ConclusionsThe EHR systems and national registers can be used for research purposes in Finland. The realization of diabetes treatment national guidelines are followed in primary care to a large extent. However, the subsequent intensification of therapy was delayed and occurred at elevated Hba1c levels.
Subject: Diabetes
Electronic health records
Drug treatment
Current care guidelines
Type 2 diabetes
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Niskanen2018_Ar ... betesAndTreatmentInten.pdf 1.133Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record